polymorphism position NUMBER alters receptor vitro aim compare development tolerance homozygous patients patients harboring wild genotype homozygous regular treatment salmeterol prospective randomized placebocontrolled study NUMBER subjects mild moderate asthma NUMBER NUMBER received NUMBER weeks treatment inhaled salmeterol NUMBER microg bid dose responses inhaled salbutamol constructed forced expiratory volume NUMBER sec fev1 heart rate qtc interval serum potassium glucose finger tremor protective effect salbutamol adenosine monophosphate amp challenge measured salmeterol resulted significant reduction area curve auc fev1 p NUMBER heart rate p NUMBER qtc interval p NUMBER tremor p NUMBER maximum responses fev1 p NUMBER heart rate p NUMBER glucose p NUMBER protective effect salbutamol amp reduced NUMBER doubling doses p NUMBER differences patients small nonsignificant tolerance influenced vitro polymorphism magnitude differences vivo unlikely significant beta2 adrenoceptor regulation beta agonist gly NUMBER arg NUMBER double blind cross gly NUMBER arg NUMBER gly NUMBER arg NUMBER beta2 adrenoceptor genotype